The browser-based tool for a radiogenomics-based CDSS for advanced NPC

$#msg#$

High risk, biopsy-based gene expression testing is required to guide treatment:

$#msg#$

Low risk (CCRT-preferred group), recommended treatment regimen: CCRT

Predicted average 5-year DFS with CCRT: 83.3%

ICT-preferred group, recommended treatment regimen: : ICT+CCRT

Predicted average 5-year DFS: 72.5%

Survival benefit compared to CCRT: 22.5%

Clincial trial-preferred group, recommended treatment regimen: clincial trial

Predicted average 5-year DFS : 61.3% regardless of CCRT or ICT+CCRT